ABVC BioPharma (ABVC)
(Delayed Data from NSDQ)
$0.68 USD
-0.01 (-1.37%)
Updated Aug 30, 2024 03:50 PM ET
After-Market: $0.68 0.00 (0.70%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ABVC 0.68 -0.01(-1.37%)
Will ABVC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ABVC based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ABVC
ABVC BioPharma GAAP EPS of -$0.09
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
ABVC BioPharma reports Q2 EPS (9c) vs (68c) last year
ABVC Stock Earnings: ABVC BioPharma Reported Results for Q2 2024
ABVC Biopharma files to sell 1M shares of common stock for holders